Sign In
Buy QGEN
$37.56
+1.11 (+3.05%)
At Close: Jun 04, 2026
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
11:03am, Wednesday, 30'th Jun 2021
QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.
Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories
04:07pm, Tuesday, 29'th Jun 2021
SAN DIEGO & HILDEN, Germany & GERMAN TOWN, Md.--(BUSINESS WIRE)-- #DNAprofiling--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and Verogen Inc. today announced a partnership to provide labo
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions
04:05pm, Tuesday, 29'th Jun 2021
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #forensics--QIAGEN partners with Verogen to offer broadest portfolio for human identification, including next generation sequencing solutio
Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments
06:45am, Tuesday, 22'nd Jun 2021
Qiagen NV (NYSE: QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function. QiaPrep&Amp CRISPR Kit and Q-Primer Solutions expand Qiag
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
04:05pm, Monday, 21'st Jun 2021
HILDEN, Germany, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #CRISPR--QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments
QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS
03:02pm, Tuesday, 01'st Jun 2021
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #fda--QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours
QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm
06:46am, Thursday, 27'th May 2021
QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.
QIAGEN (QGEN) Gains from FDA's EUA for Antibody Total Test
10:31am, Tuesday, 18'th May 2021
QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
06:15am, Monday, 17'th May 2021
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces creation of Scientific Advisory Board and agenda for Annual General Meeting in June 2021
QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA
10:32am, Friday, 14'th May 2021
QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.
QIAGEN's (QGEN) CEO Thierry Bernard on Q1 2021 Results - Earnings Call Transcript
01:28am, Wednesday, 05'th May 2021
QIAGEN's (QGEN) CEO Thierry Bernard on Q1 2021 Results - Earnings Call Transcript
QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up
09:02am, Tuesday, 04'th May 2021
QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.
Qiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost Revenues
07:10am, Tuesday, 04'th May 2021
Qiagen NV (NYSE: QGEN) on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst consensus by $9.68 million. Adjusted E
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
06:49pm, Monday, 03'rd May 2021
Qiagen (QGEN) delivered earnings and revenue surprises of 4.76% and 2.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
